165 related articles for article (PubMed ID: 121486)
1. [Coadjuvant action of chemotherapy and immunotherapy in the carcinoma of the bladder].
Rodrigues-Netto Júnior N; Napoli F; Lemos GC
Rev Paul Med; 1979; 94(3-4):51-3. PubMed ID: 121486
[No Abstract] [Full Text] [Related]
2. [Comparative study of treatments of bladder carcinoma: TUR, thiotepa or BCG].
Rodrigues Netto Júnior N; Caserta Lemos G
Arch Esp Urol; 1981; 34(5):369-74. PubMed ID: 6800309
[No Abstract] [Full Text] [Related]
3. BCG versus thiotepa in non-CIS, stage Ta, T1 bladder cancer: rationale and design of ECOG trial.
Fisher HA
Prog Clin Biol Res; 1989; 310():275-83. PubMed ID: 2505271
[No Abstract] [Full Text] [Related]
4. Intravesical therapy comparing BCG, adriamycin, and thiotepa in 200 patients with superficial bladder cancer: a randomized prospective study.
Martinez-Pineiro JA; Jimenez León J; Martinez-Pineiro L; Fiter L; Mosteiro JA; Navarro J; García Matres MJ; Cárcamo P
Prog Clin Biol Res; 1989; 310():237-52. PubMed ID: 2505269
[TBL] [Abstract][Full Text] [Related]
5. [Adjuvant local BCG-immunotherapy in patients with urothel cancer of the bladder (author's transl)].
Flamm J; Grof F
Wien Med Wochenschr; 1981 Oct; 131(20):501-6. PubMed ID: 7314632
[TBL] [Abstract][Full Text] [Related]
6. [Clinical experience with BCG immune prevention in superficial bladder cancer].
Bach D; Romics I; Rüssel C
Urologe A; 1992 Sep; 31(5):296-301. PubMed ID: 1302409
[TBL] [Abstract][Full Text] [Related]
7. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
Lamm DL; Blumenstein BA; Crissman JD; Montie JE; Gottesman JE; Lowe BA; Sarosdy MF; Bohl RD; Grossman HB; Beck TM; Leimert JT; Crawford ED
J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480
[TBL] [Abstract][Full Text] [Related]
8. The influence of Tice strain BCG treatment in patients with transitional cell carcinoma in situ.
Brosman S
Prog Clin Biol Res; 1989; 310():193-205. PubMed ID: 2771993
[No Abstract] [Full Text] [Related]
9. The optimal management of T1G3 bladder cancer.
Emiliozzi P; Pansadoro A; Pansadoro V
BJU Int; 2008 Nov; 102(9 Pt B):1265-73. PubMed ID: 19035891
[No Abstract] [Full Text] [Related]
10. T2a transitional cell carcinoma of the bladder: long-term experience with intravesical immunoprophylaxis with bacillus Calmette-Guerin.
Volkmer BG; Gschwend JE; Maier SH; Seidl-Schlick EM; Bach D; Romics I
J Urol; 2003 Mar; 169(3):931-4; discussion 934-5. PubMed ID: 12576815
[TBL] [Abstract][Full Text] [Related]
11. Contemporary management of stage T1 transitional cell carcinoma of the bladder.
Sataa S; Yassine N; Ghassen HH; Imed BS; Mohamed C; Maher C; Ali H
Tunis Med; 2005 Dec; 83 Suppl 12():87-9. PubMed ID: 16430077
[No Abstract] [Full Text] [Related]
12. Intravesical chemotherapy.
Prout GR
Prog Clin Biol Res; 1984; 162B():125-50. PubMed ID: 6438639
[No Abstract] [Full Text] [Related]
13. [The preventive recurrent results of postoperative intravesical instillation therapy in bladder cancer].
Zhang S; Li H; Cheng H
Zhonghua Wai Ke Za Zhi; 1995 May; 33(5):304-6. PubMed ID: 7587700
[TBL] [Abstract][Full Text] [Related]
14. Bladder tumors invading the lamina propria (stage T1): influence of endovesical BCG therapy on recurrence and progression.
Boccon-Gibod L; Leleu C; Herve JM; Belas M; Steg A
Prog Clin Biol Res; 1989; 310():161-9. PubMed ID: 2771991
[TBL] [Abstract][Full Text] [Related]
15. [Treatment and follow-up of superficial bladder cancer].
Raitanen M
Duodecim; 2002; 118(9):903-9. PubMed ID: 12238168
[No Abstract] [Full Text] [Related]
16. Superficial bladder disease: case studies and therapeutic advances.
Soloway MS; Droller MJ; Flanigan RC; Nseyo UO
Urology; 1992 Dec; 40(6 Suppl):11-22. PubMed ID: 1466118
[No Abstract] [Full Text] [Related]
17. Immunoprophylaxis of superficial bladder cancer: a prospective and randomized comparison of oral versus intravesical Bacillus Calmette-Guerin.
Netto Júnior NR; Levi d'Ancona CA; Claro JF; Ilari O
Arch Esp Urol; 1991 Oct; 44(8):1025-8. PubMed ID: 1796850
[TBL] [Abstract][Full Text] [Related]
18. Adriamycin versus BCG in superficial bladder cancer: a Southwest Oncology Group Study.
Lamm DL; Crissmann J; Blumenstein B; Crawford ED; Montie J; Scardino P; Grossman HB; Stanisic T; Smith J; Sullivan J
Prog Clin Biol Res; 1989; 310():263-70. PubMed ID: 2672016
[No Abstract] [Full Text] [Related]
19. [Prophylactic effects of zhuling and BCG on postoperative recurrence of bladder cancer].
Yang DA; Li SQ; Li XT
Zhonghua Wai Ke Za Zhi; 1994 Jul; 32(7):433-4. PubMed ID: 7842985
[TBL] [Abstract][Full Text] [Related]
20. Recurrence and progression of stage T1, grade 3 transitional cell carcinoma of the bladder following intravesical immunotherapy with bacillus Calmette-Guerin.
Brake M; Loertzer H; Horsch R; Keller H
J Urol; 2000 Jun; 163(6):1697-701. PubMed ID: 10799163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
